| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 2388.5 | 2392.5 | 2246.7 |
| Other income | 93.7 | 20.2 | 25.8 |
| Total income | 2482.2 | 2412.7 | 2272.5 |
| Profit before exceptional items & tax | 450.3 | 428.3 | 333.1 |
| Exceptional items | 45.8 | -17.6 | 205.1 |
| Profit before tax | 404.4 | 446.0 | 128.0 |
| Net profit | 306.7 | 363.7 | 64.0 |
| Operating margin | 16.3% | 18.5% | 5.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +379.20% |
|---|---|
| Net profit, quarter on quarter | -15.70% |
| Revenue, year on year | +6.30% |
BSE results filing, NSE: IPCALAB. Figures extracted from the filing.
Ipca Laboratories Ltd: key numbers
- Share price
- ₹1,970.80
- Market cap
- ₹50,000 Cr
- Revenue (annual)
- ₹9,646 Cr
- Net profit (annual)
- ₹1,141 Cr
- P/E (TTM)
- 38.2×Sector 50.4×
- Promoter holding
- 44.72%+0.00% QoQ
- FII holding
- 10.72%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ipca Laboratories Ltd
All →Ipca Laboratories Earnings Call Transcript: Key Takeaways
Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.
- Call
- Guides 16% growth
Ipca Laboratories Q1 FY27 Results: Net Profit ₹424.3 Cr, Up 82.2% YoY
Ipca Laboratories Ltd reported revenue from operations of ₹2,788 Cr (+20.8% YoY) and net profit of ₹424.3 Cr (+82.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹424.3 Cr · +82.2% YoY
Ipca Laboratories Earnings Call: Key Takeaways
Ipca Labs reports 8% FY26 consolidated revenue growth to ₹9,646cr. Management focuses on margin improvement and volume-led growth in domestic and US markets.